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Abstract
Background: Germline mutations in either of the two tumor-suppressor genes, BRCA1 and BRCA2, account for a
significant proportion of hereditary breast and ovarian cancer cases. Most of these mutations consist of deletions,
insertions, nonsense mutations, and splice variants, however an increasing number of large genomic
rearrangements have been identified in these genes.
Methods: We analysed BRCA1 and BRCA2 genes by direct sequencing and MLPA. We confirmed the results by an
alternative MLPA kit and characterized the BRCA1 deletion by Array CGH.
Results: We describe the first case of a patient with no strong family history of the disease who developed early-
onset bilateral breast cancer with a de novo complete BRCA1 gene deletion in the germinal line. The detected
deletion started from the region surrounding the VAT1 locus to the beginning of NBR1 gene, including the RND2,
ΨBRCA1, BRCA1 and NBR2 complete genes.
Conclusion: This finding supports the large genomic rearrangement screening of BRCA genes in young breast
cancer patients without family history, as well as in hereditary breast and ovarian cancer families previously tested
negative for other variations.
Background
Breast cancer is the most common cancer among
women, excluding non-melanoma skin cancers, and
constitutes, after lung cancer, the second leading cause
of cancer deaths in women. According to the American
Cancer Society, about 1.3 million women will be diag-
nosed with breast cancer annually worldwide, and about
465,000 will die from this disease [1]. About 5-10% of
all breast cancers are estimated to be hereditary, and
germline mutations in the tumor-suppressor genes
BRCA1 (MIM#113705) and BRCA2 (MIM#600185) are
found in a proportion of this group [2,3]. Family history
of breast and ovarian cancer, besides breast cancer bila-
terality, early-onset breast cancer and ethnicity, consti-
tute the basic criteria for identifying cases affected by
BRCA1 or BRCA2 mutations. However, a negative
family history does not exclude the presence of a germ-
line mutation in these genes; in fact, in unselected popu-
lations, the estimated prevalence of BRCA1 mutations in
medullary and triple negative breast cancers is about
18% before age 50 [4-8].
Most of the reported BRCA1 and BRCA2 mutations
are characterized by deletions, insertions, nonsense
mutations and splice variants that result in a truncated
protein. Nevertheless, an increasing number of large
genomic rearrangements (LGRs), not detectable by cur-
rent PCR-based methods, have been identified in these
genes [9], mainly due to the development of the multi-
plex-ligation-dependent probe amplification (MLPA)
procedure that allows the screening of LGRs in a large
number of samples. Prior to MLPA, LGRs were analysed
by different approaches such as Southern-blot, long-
range PCR, fluorescence in situ hybridization-based
methods and real-time PCR. LGRs in BRCA1 are
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responsible for between 0 and 27% of all BRCA1 dis-
ease-causing mutations identified in different popula-
tions [9] whereas in the case of BRCA2 these
rearrangements are rare, except for a Portuguese popu-
lation with a founder rearrangement [c.156_157insAlu
(NG_012772.1:g.8686_8687insAlu)] that explains more
than a quarter of BRCA mutations [9,10].
Identification of BRCA mutation carriers allows non-
directive clinical decisions to be made [11], in the man-
agement of high lifetime risk of breast and ovarian can-
cer including follow-up, prophylactic mastectomy and
salpingo-oophorectomy. Furthermore, mutations in
BRCA have been shown to be predictive of a good
response to certain treatments. For example, in a neoad-
juvant setting with cisplatin, an 83% pathologic com-
plete response rate in BRCA1 breast cancer carriers has
been reported [12]. Furthermore, treatment with the
new Poly(ADP)-Ribose Polymerase inhibitors, still under
clinical development, has shown promising results in
targeting the BRCA-related homologous recombination
pathway [13-16].
We report the first case of a patient with no strong
family history of the disease, with a de novo complete
BRCA1 gene deletion demonstrated by Array CGH that
developed early-onset bilateral breast cancer.
Methods
Patients
A 39 year-old woman with bilateral metachronous
breast cancer (at 28 and 37) was referred from the Ser-
vice of Medical Oncology to the Unit of Genetic Coun-
selling of hereditary cancer of our institution. After a
pre-genetic work-up and a psychological interview,
informed consent and a blood sample were obtained to
perform direct sequencing and MLPA analysis of
BRCA1 and BRCA2. Written consent to publish the
information herein reported was also obtained from the
patient.
The case herein described presented no previous
family history of breast or ovarian cancer (Figure 1),
although the mother was surgery treated with a bilateral
hysterectomy and oophorectomy at age 41 for a benign
process. In 1998, our case (28 years-old) developed an
infiltrating ductal carcinoma in the right breast
(pT1cpN0M0) and was treated with quadrantectomy
and axillary lymphadenectomy followed by external
radiotherapy and interstitial brachytherapy, and 5 cycles
of AC (cyclophosphamide, doxorubicin). Eight years
later (at age 37), a medullary carcinoma was diagnosed
in the contralateral breast (pT2pN0M0). On this occa-
sion, the treatment consisted of 4 cycles of liposomal
doxorubicin followed by external radiotherapy. In both
cases the tumors expressed hormonal receptors and
HER2.
As a BRCA1 LGR was identified, a prophylactic sur-
gery was proposed, although finally the patient opted for
a yearly follow-up consisting of mammography, transva-
ginal echography and measurement of serum levels of
CA125.
Close relatives were invited to complete the segrega-
tion study and informed consent was obtained from the
mother, father and two sisters. All of them were nega-
tive for this LGR. One brother, with a one year mentally
retarded daughter, refused the genetic study.
Mutation analysis of BRCA1 and BRCA2
Genomic DNA was isolated from peripheral blood sam-
ples with the automatic Magtration System 12GC and
the Magtration-MagaZorb DNA Common kit (Precision
System Science Co. Ltd.). DNA integrity was evaluated
by the A260/A280 absorbance ratio with a Nanodrop-
1000 (NanoDrop ND1000, NanoDrop Technologies,
Wilmington, Delaware USA) spectrophotometer. Muta-
tional screening of BRCA1 and BRCA2 genes was car-
ried out by direct sequencing using the VariantSeq
RSS000009249_03 and RSS000009432_04 assays
(Applied-Biosystems, Foster City, USA), respectively,
and specific primers to complete the sequence of both
genes (primer sequences available upon request). DNA
sequencing was performed directly on PCR purified pro-
ducts using the Big Dye terminator v3.1 sequencing kit
(Applied-Biosystems, Foster City, USA). Capillary gel
electrophoresis and data collection were carried out on
an automated DNA sequencer ABI PRISM 3130XL
(Applied-Biosystems). Sequence analyses were carried
out with Seq-scape Software v2.6 (Applied-Biosystems).
Mutation nomenclature is in accordance with the
Human Genome Variation Society (HGVS) (http://www.
hgvs.org/mutnomen/). The reference sequences used for
BRCA1 and BRCA2 are NM_007294.2 and
NM_000059.3 respectively from the NIH GeneBank
(http://research.nhgri.nih.gov/bic/).
LGR detection by Multiplex Ligation-dependent Probe
Amplification (MLPA)
As no significant mutations were found by direct
sequencing, BRCA1 LGR was quantified by MLPA
using the P002 probe mix assay according to the man-
ufacturer’s instructions (MRC Holland). Once a posi-
tive result was obtained, a confirmatory analysis was
independently performed with the BRCA1 P087 assay
(MRC Holland). Amplified products were separated
using an ABI PRISM 3130XL (Applera) genetic analy-
zer and interpreted using GeneMapper Software v4.0
(Applied-Biosystems). Quantitation of the results of
fragment analysis was performed using the Excel soft-
ware by calculating relative peak areas as described by
the manufacturer (MRC Holland). Different normal
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control samples were used to normalize the allele
dosage.
Comparative Genome Hybridization (CGH) Array
Array CGH was performed once a complete deletion of
BRCA1 was noticed by MLPA. Non-amplification label-
ling of DNA (direct method) was obtained following the
‘Agilent Oligonucleotide Array-Based CGH for Genomic
DNA Analysis’ protocol Version 5.0 (Agilent Technolo-
gies, Palo Alto, California USA. p/n G4410-90010). Two
μg of experimental and reference genomic DNA samples
were fragmented in a restriction digestion step. Diges-
tion was confirmed and evaluated by DNA 7500 Bioana-
lyzer assay. Cyanine 3-dUTP and cyanine 5-dUTP were
used for the respective fluorescent labelling of test and
reference-digested gDNAs using the ‘Agilent Genomic
DNA Labelling Kit PLUS’ (Agilent p/n 5188-5309)
according to the manufacturer’s instructions. Labelled
DNA was hybridized with the Human Genome CGH
Microarray 244K (Agilent p/n G4423B-014693) contain-
ing 236,381 distinct biological features covering the
human genome at an overall median probe spacing of
7.4 KB in Refseq genes. Arrays were scanned in an Agi-
lent Microarray Scanner (Agilent G2565BA) according
to the manufacturer’s protocol, and data extracted using
Agilent Feature Extraction Software 10.7.1 following the
Agilent protocol CGH_107_Sep09, grid template
014693_D_F_20090929 and the QC Metric Set
CGH_QCMT_Sep09. CGH data were analysed and
visualized using the Genomic Workbench Standard Edi-
tion 5.0 (Agilent Technologies) software. The human
reference sequence employed was the March 2006
NCBI36/hg 18 produced by the International Human
Genome Sequencing Consortium.
Exclusion of non-paternity
Once the absence of BRCA1 deletion was demonstrated
in the parents of our case, a set of twelve polymorphic
tetranucleotide repeats was analysed by three fluorescent
multiplex PCR in order to exclude non-paternity [17].
Products were separated by capillary electrophoresis and
analysed using GeneMapper Software v4.0 (Applied-
Biosystems).
Assignment of parental origin
To determine whether the mutation occurred on the
maternal or paternal allele, we analysed seven BRCA1
intragenic polymorphisms (rs8176144, rs1799949,
Figure 1 Patient’s family pedigree displaying breast cancer. Black shading indicates individuals with cancer. The patient (proband) is
individual III:2 and is arrowed. The current age and the age at diagnosis of cancers are indicated below. The genotypes (where DNA available
for analyses) are shown as: - for wild-type homozygous, and + for heterozygous for BRCA1 complete deletion. PC: prostate cancer; CLL: chronic
lymphocytic leukaemia; CRC: colorectal cancer; BC: breast cancer; Bi BC: bilateral breast cancer.
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rs16940, rs1799966, rs3092987, rs8176235 and
rs11654396) by direct sequencing.
Copy Number Variation (CNV) Analysis
Copy number analysis of ZFPM2 was performed for the
proband, her mother, father, two sisters and two con-
trols, using the TaqMan® Copy Number Assays (CNA)
(Applied Biosystems). Three assays were selected for
this purpose, one being located in proximity to the 5’-
end of the ZFPM2 gene (HS06234652_cn), one near the
3’-end (HS02556672_cn), and the TaqMan Copy Num-
ber reference assay (RNase P), which is known to exist
only in two copies in a diploid genome. Each DNA sam-
ple was analysed in quadruplicate. Reactions were per-
formed according to the manufacturer’s instructions and
processed in an ABI 7500 Fast Real Time PCR System
(Applied Biosystems). Data was collected by the SDS
software (version 2.01; ABI) using the standard absolute
quantification method. After the reaction, raw data was
analysed using a manual cycle threshold (Ct) of 0.2 with
the automatic baseline on, and then imported to the
CopyCallerTM Software (version 1.0; ABI) for post-PCR
data analysis. In the software, copy numbers were esti-
mated using a maximum likelihood algorithm.
Results
Mutation analysis of BRCA1 and BRCA2
The analysis of the complete coding and exon-intron
boundary sequences of BRCA1 and BRCA2 revealed no
frameshift or missense mutations. Only a previously
uncharacterized base change in the position IVS6+14 C
> T (c.516+14 C > T according to HGVS nomenclature)
of BRCA2 gene was found. Using bioinformatics tools,
such as ESEfinder (http://rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process=home) to identify exonic
splice enhancer motifs; Splice Site Prediction by Neural
Network (Berkeley Drosophila Genome Project) (http://
www.fruitfly.org/seq_tools/splice.html), and Human Spli-
cing Finder (http://www.umd.be/HSF/) to identify puta-
tive splice sites [18], this change was predicted not to
affect splicing.
MLPA analysis of BRCA1 and BRCA2
Once direct DNA sequencing had detected no signifi-
cant genetic variations, we proceeded to the LGR analy-
sis of BRCA1 by MLPA (BRCA1 P002). The case
showed an MLPA profile suggestive of a deletion invol-
ving the complete BRCA1 gene (Figure 2A). The analy-
sis was confirmed by MLPA using the BRCA1 P087 kit
with the same resulting profile (Figure 2B). Genetic
counselling and testing of the BRCA1 deletion were
offered to the patient’s relatives (Figure 1). MLPA analy-
sis of BRCA1 was carried out on blood samples from
both parents and from the two proband’s sisters, all
showing negative results for BRCA1 deletion. In order
to confirm paternity, a set of twelve polymorphic tetra-
nucleotide repeats was analysed on DNA from the
patient and both parents, the results were consistent
with the reported paternity (data not shown). On the
other hand, to determine whether the mutation
occurred on the maternal or paternal allele, we analysed
seven BRCA1 intragenic polymorphisms for both par-
ents and compared their haplotypes with the haplotype
of their daughter indicating that the BRCA1 deletion
arose in the mother’s germ cells (data not shown).
Array CGH
With the aim of characterizing the deleted region, a
microarray-based comparative genomic hybridization
(CGH) was performed using high-resolution oligonu-
cleotide microarray (Human Genome CGH Microarray
244 K). Oligonucleotide whole genome array CGH ana-
lysis showed that the 5’ boundary of the affected region
is located at the beginning of the NBR1 gene whereas
the 3’ boundary is located around the VAT1 locus,
including the RND2, ΨBRCA1, BRCA1 and NBR2 com-
plete genes with an approximate size of 0.15 Mb (Figure
3A).
Moreover, another chromosomal abnormality was
detected in the long arm (q) of chromosome 8. Specifi-
cally, an amplification of the region corresponding to
the ZFPM2 locus was detected (Figure 3B). These
changes did not correspond to CNV according to Geno-
mic Workbench Standard Edition 5.0. These data were
confirmed using two CNA of ZFPM2 gene in the pro-
band, her mother, father and two sisters and two control
samples. The confidence of prediction for both CNA
was greater than 95% in each subject. All the samples
were predicted to have 2 copies of the ZFPM2 gene by
any assay excepting the proband sample, which was pre-
dicted to have 2.68 and 2.37 copies of the target
sequence by assays at the 5’-end of the gene and the 3’-
end respectively (Figure 4). Therefore, this subject is
likely to have more than 2 gene copies.
Discussion
In the present study, we describe a de novo deletion of
BRCA1 in the germinal line of an early-onset breast can-
cer patient. To our knowledge, this represents the third
case of a Hereditary Breast and Ovarian Cancer patient
with a complete BRCA1 gene deletion [19,20]. This rear-
rangement was detected by MLPA and characterized by
Array CGH analysis. The deleted area started from the
region surrounding the VAT1 (MIM#604631) locus to
the beginning of NBR1 (MIM#166945) gene, including
the RND2 (MIM#601555), ΨBRCA1, BRCA1
(MIM#113705) and NBR2 complete genes. NBR1 was
originally cloned as a candidate for the ovarian cancer
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antigen CA125 [21], but no involvement in breast or
ovarian cancer has been demonstrated. NBR1 has been
described as a highly conserved multidomain scaffold
protein involved in targeting ubiquitinated proteins for
degradation [22]. No functions have been ascribed to
either the ΨBRCA1 or the NBR2 genes, which seem to
result from a duplication event [23]. Regarding RND2,
which is a RHO family small GTPase, this is involved in
regulating the migration and morphological changes
associated with the development of pyramidal neurons
[24]. Finally, VAT1 codifies for a synaptic vesicle integral
membrane protein [25].
Inadvertently, we also detected an amplification of the
region corresponding to the ZFPM2 locus (8q23) which
did not affect any of the analysed relatives. ZFPM2
(MIM#603693) encodes a zinc finger protein member of
the FOG family of transcription factors implicated in
heart morphogenesis and cardiogenesis. Defects in this
gene may be a cause of tetralogy of Fallot (TOF), a con-
genital heart anomaly, and are also the cause of a form
of congenital diaphragmatic hernia (CDH). However,
our patient did not show any clinical evidence in this
regard. BRCA genes are involved in the repair of DNA
double-strand breaks (DSBs) by homologous recombina-
tion maintaining the genetic stability during cell divi-
sion. In the absence of functional BRCA1 or BRCA2
DSBs are repaired by an error-prone non-homologous
end-joining mechanism that provokes mutations and
genomic instability [26]. The case herein reported is
deficient in BRCA1 and we may speculate that it would
Figure 2 MLPA analysis of the BRCA1 gene performed with the SALSA MLPA KIT P002 (panel A) and P087 (panel B) (MRC-Holland).
Graph displaying the ratios between the relative peak areas for proband and controls. Grey and black bars correspond to BRCA1 and control
probes respectively. The analysis revealed a 50% decreased amplification of the probes corresponding to BRCA1 gene.
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Figure 3 Representative array CGH profile in the proband. (A) Schematic representation of Array CGH analysis on chromosome 17. A single-
copy deletion from the beginning of NBR1 to the VAT1 locus, including the RND2, ΨBRCA1, BRCA1 and NBR2 complete genes is shown. (B)
Schematic representation of Array CGH analysis on chromosome 8. A mosaicism for an amplification of the region corresponding to the ZFPM2
locus could be appreciated.
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be prone to accumulate genetic instabilities that in this
case affect the ZFPM2 region.
The great peculiarity of the case herein reported is
that the BRCA1 deletion is not present in any other
family member, including both parents. Therefore, it
would constitute the first case of a patient with a de
novo whole-gene BRCA1 deletion.
Since the incorporation of LGR analysis into the
standard practice of genetic counselling laboratories
the number of LGRs reported have almost tripled for
BRCA1 and sextupled for BRCA2 just in the last 4
years, including at least 81 different LGRs in BRCA1
[9]. Most of the characterized LGRs in BRCA1 have
been described throughout the gene as intragenic dele-
tions or duplications resulting from unequal recombi-
nation events between Alu sequences; the majority are
unique, and generally introduce a premature termina-
tion codon in the reading frame. This fact is justified
by the genetic structure of BRCA1 with numerous
intragenic Alu repeats (41.5%) [25], which are known
to mediate the occurrence of rearrangements, and with
a BRCA1 pseudogene 30 kb upstream [27,28]. Several
studies have described germline LGRs involving either
Alu repeats or the BRCA1 pseudogene [29]. However,
to our knowledge, only one LGR without involvement
of these genetic structures has so far been reported
[30].
The frequency of these LGRs in the BRCA1 gene var-
ies from 0% in Iranian, Afrikaner and French-Canadian
populations, to 27% in the Dutch population [9,31-33].
According to Sluiter and van Rensburg [9] the propor-
tion of LGRs detected in the Hispanic population is
over a 10%, probably as consequence of a single founder
deletion of exons 9-12 [34]. The size of these BRCA1
LGRs varies from 244 bp, the smallest size deleting
exon 5 (NG_005905.2:g.111421_111664del) [35], to tens
of kilobases removing the complete BRCA1gene. As far
as we know, there are only two Hereditary Breast and
Ovarian Cancer families with LGRs including a whole-
gene BRCA1 deletion reported to date [19,20]. De la
Hoya et al. [19] reported a Spanish family (HSP-198)
with a complete deletion of BRCA1 that segregates with
the disease within the family. The alteration was tested
by MLPA with the BRCA1 P002 probe mix assay and
confirmed with the alternative set of probes P087,
although no other molecular technique was employed.
Moreover, they did not characterize the region affected
by the deletion. In 2008, Konecny et al. [20] also identi-
fied a complete BRCA1 gene deletion using a combina-
tion of SNP haplotype analysis, MLPA (kits P002 and
Figure 4 Copy number of the ZFPM2 gene in the proband, her mother, father, two sisters and two control samples. Each bar represents
the copy number prediction of the target sequence in each subject and different colors correspond to each copy number assay (grey:
Hs02556672_cn, black: Hs06234652_cn). Thus, each individual is represented by two bars. The broken line indicates the reference line for two
copies.
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P0087) and a confirmatory Array CGH analysis. The
alteration was also tested to segregate with the disease
in the affected family. Excepting these reports, the lar-
gest described BRCA1 deletion involves 160,880 bp,
(NG_005905.2:g.8836_169713del), removing more than
95% of the BRCA1 sequence (exons 1-22), ΨBRCA1,
NBR2 and 18 of the 19 NBR1 exons [36].
Regarding the fact that the LGR identified in the pro-
band is a de novo mutation, the incidence of de novo
BRCA mutations among gene carriers is unknown, but
seems to be very low. To date, just seven cases of de
novo BRCA mutations have been reported in the litera-
ture, only two in the BRCA1 gene and five in BRCA2
[37-43] (Table 1). Concerning de novo mutations in
BRCA1, Tesoriero et al. [38] report a woman with early-
onset breast cancer with two germline protein-truncat-
ing mutations: BRCA1 c.3769_3770delGA and BRCA2
c.5946delT. The BRCA2 mutation was inherited from
the father and the BRCA1 mutation was de novo arising
also from the father in a testicular germ cell. The sec-
ond described BRCA1 de novo mutation (c.5332+1G >
A in intron 21) was reported by Edwards et al. [42] in a
young woman with early bilateral breast cancer and lim-
ited family history. With respect to de novo mutations
in BRCA2, van der Luijt et al. [40] identified a de novo
recurrent germline mutation in BRCA2 (c.3034del4) in a
patient with early-onset breast cancer and no strong
family history of disease, this was the first case with a de
novo mutation identified in BRCA2. In 2002 Robson et
al. [39] reported a previously undescribed de novo muta-
tion in exon 14 of BRCA2 (c.7260insA) that results in a
premature termination at codon 2359 in a patient diag-
nosed at 35 with bilateral infiltrating ductal carcinoma
and without family history of breast or ovarian cancer
(five sisters aged 32 to 47, and mother alive and without
cancer at 71). Hansen et al. [43] described in 2008 the
third case of a de novo BRCA2 mutation. This was a
novel variant at the splice site of exon 21 (c.8754+1 G >
A) in a patient with a ductal carcinoma at the age of 40,
with a family history of breast cancer (mother affected
at the age of 59), while the novel mutation arose in the
male germ line. The two remaining reported mutations
were described by Marshall et al. [41] and Diez et al.
[37] in 2009 and 2010 respectively. Marshall et al. [41]
presented a de novo BRCA2 mutation (c.5301insA) in a
35-year-old woman with breast cancer and no strong
family history of disease, meanwhile Diez et al. [37]
identified a novel de novo BRCA2 mutation (c.51dupA)
in a patient with early-onset bilateral breast cancer and
no family history of disease, also located in the paternal
allele.
Conclusions
In conclusion, a relevant number of reports exist of
BRCA germline mutations in patients with early-onset
breast cancer without a strong family history of disease.
These studies, including the case herein described,
underline the importance of mutation screening, includ-
ing LGR analysis, especially in cases where tumors are
high grade and bilateral. The absence of family history
might be related to non-informative families or to the
fact that all germ line mutations started as a de novo
Table 1 BRCA1 and BRCA2 de novo mutations.
Gene affected
by de novo
mutation
Designation* Clinical Characteristics Cancer family history Reference
BRCA1 c.3769_3770delGA Age < 40 years
High-grade BC with axillary nodal
metastases.
Father with prostate carcinoma at 50s.
Inherited BRCA2 mutation c.5946delT
[38]
BRCA1 c.5332+1G > A Bilateral IDC BC at 38 (ER+, grade II)
and 43 years-old (ER and PR+, grade III).
Maternal aunt with BC prior to her death at 54 years-
old.
[42]
BRCA2 c.3034del4 Multifocal BC with axillary node
metastases at 39 years of age.
A cousin on the paternal side with BC diagnosed at the
age of 54.
[40]
BRCA2 c.7260insA At age 35 with bilateral IDC. Father with colon cancer at the age of 57 and died of
metastatic disease at 62
[39]
BRCA2 c.8754+1 G > A IDC BC at the age of 40 (ER and PR +,
grade II).
Mother with BC at 59 years-old. [43]
BRCA2 c.5301insA At the age of 35 grade III IDC BC (ER+,
PR- and HER2-).
Paternal grandmother BC at age 42 and paternal first
cousin with prostate cancer at age 40.
Maternal family history with diagnosis of OC in great-
grandmother and great-great-grandmother, and a great-
aunt with BC in her 70s.
[41]
BRCA2 c.51dupA Diagnosed at the ages of 27 (ER and
PR -) and 37 (ER and PR +, HER2 -) with
bilateral IDC BC.
No other breast or ovarian cancers were present. [37]
* Designation of genetic alterations is maintained as previously cited in the original references.
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mutation in some ancestor, despite the low incidence of
detected de novo BRCA mutations.
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